Guardian Partners Inc. Takes Position in ARK Genomic Revolution ETF $ARKG

Guardian Partners Inc. bought a new stake in ARK Genomic Revolution ETF (BATS:ARKG) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 34,800 shares of the company’s stock, valued at approximately $758,000.

Several other institutional investors and hedge funds also recently made changes to their positions in ARKG. DAVENPORT & Co LLC grew its position in ARK Genomic Revolution ETF by 4.3% during the first quarter. DAVENPORT & Co LLC now owns 20,217 shares of the company’s stock worth $420,000 after buying an additional 838 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new stake in ARK Genomic Revolution ETF during the first quarter worth approximately $387,000. Cambridge Investment Research Advisors Inc. grew its position in ARK Genomic Revolution ETF by 0.9% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 94,117 shares of the company’s stock worth $1,954,000 after buying an additional 839 shares in the last quarter. NBC Securities Inc. grew its position in ARK Genomic Revolution ETF by 137,400.0% during the first quarter. NBC Securities Inc. now owns 1,375 shares of the company’s stock worth $28,000 after buying an additional 1,374 shares in the last quarter. Finally, LPL Financial LLC grew its position in ARK Genomic Revolution ETF by 13.4% during the first quarter. LPL Financial LLC now owns 783,702 shares of the company’s stock worth $16,270,000 after buying an additional 92,444 shares in the last quarter.

ARK Genomic Revolution ETF Stock Performance

BATS ARKG opened at $25.51 on Monday. The business has a fifty day moving average price of $24.78 and a two-hundred day moving average price of $23.24. ARK Genomic Revolution ETF has a fifty-two week low of $17.51 and a fifty-two week high of $31.16.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.